RxDoctor Payments Data

Peyman Soltani, MD

Interventional Cardiology · Bellingham, WANPI 1134317092

Payments from drug & device makers

$2,354in general payments, 2019–2025

Across 47 payments — averaging $50.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Shockwave Medical, Inc$180
  • Cardinal Health 200 LLC$163
  • Terumo Medical Corporation$96
  • Novartis$63
  • AstraZeneca$60
  • plus $246 from 8 others

What the payments were for

  • Travel & lodging$69129%
  • Food & beverage$1,63069%
  • Education$331%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,354 in reported general payments places this provider in the 35th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$281,738
Medicare patients
770
Services billed
3,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban166$162,024
XareltoRivaroxaban55$43,526
JardianceEmpagliflozin32$36,440
BrilintaTicagrelor27$16,808
Repatha SureclickEvolocumab21$12,986
Metoprolol Succinate993$12,765
Ranolazine ErRanolazine90$8,058
Isosorbide Mononitrate ErIsosorbide Mononitrate721$7,399
Amlodipine Besylate828$5,564
Prasugrel Hcl38$2,281
Nitroglycerin170$1,853
Hydralazine Hcl171$1,845
Losartan Potassium230$1,690
Carvedilol201$1,581
Lisinopril248$1,564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$45$43,52655 claims
AstraZenecaBrilinta$60$16,80827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 125 interventional cardiology providers in Washington.

Other interventional cardiology in Bellingham

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →